Literature DB >> 9504515

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children.

B Lell1, D Luckner, M Ndjavé, T Scott, P G Kremsner.   

Abstract

BACKGROUND: The combination of atovaquone and proguanil is highly effective and safe for the treatment of Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis.
METHODS: 320 children who lived in a hyperendemic area for P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear.
FINDINGS: 25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0.001). Adverse events during the chemosuppression phase did not differ between the groups.
INTERPRETATION: The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Age Factors; Case Control Studies; Child; Child Health; Demographic Factors; Developing Countries; Diseases; Drugs; French Speaking Africa; Gabon; Health; Malaria--prevention and control; Middle Africa; Parasitic Diseases; Population; Population Characteristics; Research Methodology; Research Report; Studies; Treatment; Youth

Mesh:

Substances:

Year:  1998        PMID: 9504515     DOI: 10.1016/S0140-6736(97)09222-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  From Livingstone to ecotourism. What's new in travel medicine?

Authors:  S Houston
Journal:  Can Fam Physician       Date:  2000-01       Impact factor: 3.275

2.  Clinical Trials Report.

Authors:  Richard D. Pearson
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

Review 3.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Tropical medicine at the University of Tübingen.

Authors:  Peter Gottfried Kremsner
Journal:  Wien Klin Wochenschr       Date:  2010-03       Impact factor: 1.704

5.  Peer-reviewed publication of clinical trials completed for pediatric exclusivity.

Authors:  Daniel K Benjamin; Philip Brian Smith; M Dianne Murphy; Rosemary Roberts; Lisa Mathis; Debbie Avant; Robert M Califf; Jennifer S Li
Journal:  JAMA       Date:  2006-09-13       Impact factor: 56.272

6.  Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii.

Authors:  M D Ball; M S Bartlett; M Shaw; J W Smith; M Nasr; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Recent Advances in the Prophylaxis and Treatment of Malaria.

Authors:  Annie-Claude Labbé; Mona R. Loutfy; Kevin C. Kain
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

8.  Incidence of malaria among mosquito collectors conducting human landing catches in western Kenya.

Authors:  John E Gimnig; Edward D Walker; Peter Otieno; Jackline Kosgei; George Olang; Maurice Ombok; John Williamson; Doris Marwanga; Daisy Abong'o; Meghna Desai; Simon Kariuki; Mary J Hamel; Neil F Lobo; John Vulule; M Nabie Bayoh
Journal:  Am J Trop Med Hyg       Date:  2012-12-18       Impact factor: 2.345

Review 9.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 10.  Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.

Authors:  Kate McKeage; Lesley Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.